Technical Analysis for MRKR - Marker Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 5.84 0.86% 0.05
MRKR closed up 0.86 percent on Wednesday, March 20, 2019, on 85 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical MRKR trend table...

Date Alert Name Type % Chg
Mar 20 20 DMA Resistance Bearish 0.00%
Mar 20 MACD Bullish Signal Line Cross Bullish 0.00%
Mar 19 20 DMA Resistance Bearish 0.86%
Mar 19 Crossed Above 50 DMA Bullish 0.86%
Mar 19 Inside Day Range Contraction 0.86%
Mar 18 Fell Below 20 DMA Bearish 3.36%
Mar 18 Fell Below 50 DMA Bearish 3.36%
Mar 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.36%
Mar 15 Crossed Above 20 DMA Bullish -0.34%
Mar 15 Crossed Above 50 DMA Bullish -0.34%

Older signals for MRKR ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is also advancing various peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In addition, it develops a proprietary DNA expression technology, known as PolyStart, to improve the ability of the cellular immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Medicine Cancer Alpha Immunology Treatment Of Cancer Immunotherapy Oncology Immune System Cancer Treatments Cancer Immunotherapy Tumor Virotherapy Cell Therapy Immunotherapies Solid Tumor Hematological Malignancies T Cell
Is MRKR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.55
52 Week Low 2.58
Average Volume 257,203
200-Day Moving Average 7.4377
50-Day Moving Average 5.7371
20-Day Moving Average 5.842
10-Day Moving Average 5.558
Average True Range 0.4006
ADX 23.38
+DI 23.1294
-DI 11.5736
Chandelier Exit (Long, 3 ATRs ) 5.3982
Chandelier Exit (Short, 3 ATRs ) 6.4018
Upper Bollinger Band 6.5665
Lower Bollinger Band 5.1175
Percent B (%b) 0.5
BandWidth 24.80315
MACD Line -0.0266
MACD Signal Line -0.0295
MACD Histogram 0.0029
Fundamentals Value
Market Cap 59.32 Million
Num Shares 10.2 Million
EPS -1.02
Price-to-Earnings (P/E) Ratio -5.73
Price-to-Sales 0.00
Price-to-Book 3.74
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.22
Resistance 3 (R3) 6.23 6.12 6.15
Resistance 2 (R2) 6.12 6.02 6.11 6.13
Resistance 1 (R1) 5.98 5.97 6.05 5.97 6.11
Pivot Point 5.87 5.87 5.91 5.86 5.87
Support 1 (S1) 5.73 5.77 5.80 5.72 5.57
Support 2 (S2) 5.62 5.72 5.61 5.55
Support 3 (S3) 5.48 5.62 5.53
Support 4 (S4) 5.47